 |
 |
 |
 |
 |
|
|
| Article 1 to 5 out of 5 concerning Genzyme Corporation
|
-
Genzyme to Build New R&D Center in Beijing
(25 Apr 2008)
Environmentally Responsible Site to Significantly Increase Company's Presence in China
Genzyme Corp. announced that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion and commitment to establishing a long-term presence in China.The new ...
-
Genzyme Launches New Diagnostic Test for Common Blood Cancer
(31 Jul 2006)
p53 Mutation Analysis Offers Critical Prognostic and Predictive Information for B-Cell Chronic Lymphocytic Leukemia
Genzyme Corporation announced the availability of its p53 Mutation Analysis for B-cell chronic lymphocytic leukemia (B-CLL). P53 is a tumor suppressor gene that stops cell division when DNA damage is present. When the p53 gene does not function ...
-
Genzyme Releases Two New Molecular Tests for Acute Myelogenous Leukemia
(19 May 2006)
Tools Improve Treatment Management of AML Patients
Genzyme Corporation announced the availability of two new molecular tests for acute myelogenous leukemia (AML) with the launch of FLT3 Mutation Analysis and WT1 RQ-PCR. FLT3 mutations are considered a prognostic indicator of poor survival and ...
-
Genzyme Launches Key Test To Monitor Gleevec Resistance
(13 Feb 2006)
Two Additional Personalized Medicine Tests Also Available
Genzyme Corporation announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec® (imatinib mesylate). Despite high response rates to Gleevec, approximately ...
-
Genzyme Receives Waiver for OSOMR Trichomonas Rapid Test
(13 Apr 2005)
Genzyme Corporation announced that it has received a Clinical Laboratory Improvement Act (CLIA) waiver from the U.S. Food and Drug Administration for its OSOM® Trichomonas Rapid Test. This waiver significantly expands the number of clinics and ...
 |
|
|
|
|